Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
July 20, 2017 at 14:51 PM EDT
This is the second major acquisition of a bioterrorism-related countermeasures drug in two weeks for the Gaithersburg-based company.